Search company, investor...

Epiphany Biosciences

Founded Year



Series A | Alive

Total Raised




Last Raised

$36M | 16 yrs ago

About Epiphany Biosciences

Epiphany Biosciences is focused on advancing new therapies for infectious disease. The founders include Fred Volinsky MD, Robert GalloMD, David Myles Ph.D and Barry Selick Ph.D. Epiphany is located in San Francisco, California.

Headquarters Location

One California Street Suite 2800

San Francisco, California, 94111,

United States


Missing: Epiphany Biosciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Epiphany Biosciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Epiphany Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Epiphany Biosciences is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Epiphany Biosciences Patents

Epiphany Biosciences has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Viral diseases, Animal virology, Analgesics, Virology, Phenols


Application Date


Grant Date



Related Topics

Viral diseases, Animal virology, Analgesics, Virology, Phenols



Epiphany Biosciences Frequently Asked Questions (FAQ)

  • When was Epiphany Biosciences founded?

    Epiphany Biosciences was founded in 2006.

  • Where is Epiphany Biosciences's headquarters?

    Epiphany Biosciences's headquarters is located at One California Street, San Francisco.

  • What is Epiphany Biosciences's latest funding round?

    Epiphany Biosciences's latest funding round is Series A.

  • How much did Epiphany Biosciences raise?

    Epiphany Biosciences raised a total of $36M.

  • Who are the investors of Epiphany Biosciences?

    Investors of Epiphany Biosciences include CDIB BioScience Venture Management, Medivir and Wexford Capital.

  • Who are Epiphany Biosciences's competitors?

    Competitors of Epiphany Biosciences include Adamas Pharmaceuticals, FluGen, BioCardia, CoMentis, Hyperion Therapeutics and 10 more.

Compare Epiphany Biosciences to Competitors


Altheos, Inc. is an early-stage biopharmaceutical company focused on the identification and development of promising well-differentiated novel small molecule drugs for unmet medical needs. Altheos, Inc. was co-founded in 2009 by two experienced pharmaceutical drug development executives and entrepreneurs, Henry H. Hsu, M.D. and M. (Ken) Kengatharan, Ph.D. The company is headquartered in South San Francisco, California.


The company are developing siRNA drugs targeting a control factor for HIF (hypoxia-inducible factor), which is one of the main factors involved in angiogenesis. The company have found that siRNA can promote angiogenesis by inducing expression of several angiogenic factors simultaneously by preventing breakdown of HIF inside the cell. It is therefore expected that delivery of siRNA to disease-affected sites can efficiently induce angiogenesis, leading to a in treatment for obstructive arteriosclerosis.

Radius Logo

Radius Health is a biopharmaceutical company focused on developing new therapeutics to treat osteoporosis and other women's health conditions. It is committed to the development of therapeutics for the osteoporosis market. The company's lead product candidate, BA058-SC, is in effect to reduce the risk of complications associated with osteoporosis, such as fractures and has a transdermal patch, BA058-TD, being developed as a short wear-time delivery vehicle intended to improve patient compliance with convenience and ease of use, as well as a product in development to treat symptoms associated with menopause. The company was founded in 2003 and is based in Boston, Massachusetts.

Actinobac Biomed

Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Its drug candidates are based upon Leukothera (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.


Anexon, Inc., a pharmaceutical company, develops therapeutics for cardiovascular diseases. The company is based in Cambridge, Massachusetts.

CoImmune Logo

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.